Get the Stockscreener App
4.84
2.22%
-0.12
Recursion Pharmaceuticals Inc stock is traded at $4.84, with a volume of 10.71M.
It is down -2.22% in the last 24 hours and up +11.24% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$4.96
Open:
$4.902
24h Volume:
10.71M
Relative Volume:
0.38
Market Cap:
$2.52B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-3.1226
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
+3.85%
1M Performance:
+11.24%
6M Performance:
-24.57%
1Y Performance:
-35.59%
1-Day Range:
$4.7901
$4.96
1-Week Range:
$4.35
$5.24
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.8414 | 2.58B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharma director Gibson sells $178,800 in stock - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 10.8%Here's Why - MarketBeat
Biotech Stocks To Keep An Eye OnJanuary 22nd - MarketBeat
Recursion Shines at J.P. Morgan Healthcare Conference - StocksToTrade
Recursion Pharmaceuticals Boosts Visibility With J.P. Morgan Conference - timothysykes.com
How Do Investors Really Feel About Recursion Pharmaceuticals Inc? - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory - Insider Monkey
JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects - Yahoo Finance
Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX) - MSN
Is Meta Stock a Buy Going Into 2026? - AOL.com
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness - simplywall.st
Sumitomo Mitsui Trust Group Inc. Sells 701,887 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? - Yahoo Finance
Assessing Whether Recursion Pharmaceuticals (RXRX) Looks Undervalued After Recent Trading Volatility - Yahoo Finance
2 AI stocks to buy in 2026, and 1 to avoid - MSN
2 AI Stocks to Buy in 2026, and 1 to Avoid - Finviz
Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates (NASDAQ:RXRX) - Seeking Alpha
Assessing Recursion Pharmaceuticals (RXRX) Valuation After JP Morgan Update And REC-4881 Clinical Milestones - Sahm
Recursion Pharmaceuticals (RXRX) stock drops despite market gains: Important facts to note - MSN
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
How Recursion’s AI Drug Platform Progress And Extended Runway At Recursion Pharmaceuticals (RXRX) Has Changed Its Investment Story - simplywall.st
Recursion Pharmaceuticals patents PIKfyve inhibitors - BioWorld MedTech
How does Recursion Pharmaceuticals Inc score in quality rankingsStop Loss & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside Amidst Biotechnology Challenges - DirectorsTalk Interviews
Market Outlook: Is Recursion Pharmaceuticals Inc stock overvalued by current metrics2025 Retail Activity & Safe Entry Momentum Tips - Bộ Nội Vụ
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus - TechStock²
Why Recursion Pharmaceuticals Stock Is Quietly Climbing - TipRanks
Recursion Updates AI Drug Platform, Financial Outlook at JPM - TipRanks
Recursion Pharmaceuticals, Inc. Releases Updated Investor Presentation - TradingView — Track All Markets
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Recursion Pharmaceuticals Inc. stock benefit from infrastructure spendingStock Surge & Detailed Earnings Play Alerts - ulpravda.ru
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Insider Sell: Blake Borgeson Sells 220,000 Shares of Recursion P - GuruFocus
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares - MarketBeat
Recursion Pharmaceuticals Insider Sold Shares Worth $959,200, According to a Recent SEC Filing - MarketScreener
Can Recursion Pharmaceuticals Inc. stock surprise with earnings upsideJuly 2025 Macro Moves & Free Community Consensus Stock Picks - ulpravda.ru
Aug Setups: How Recursion Pharmaceuticals Inc. stock performs after earningsJuly 2025 Opening Moves & Safe Entry Momentum Tips - ulpravda.ru
Recursion pharma director Gibson sells $170k in shares By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates - Finviz
Recursion’s Stock Surge: An Opportunity? - StocksToTrade
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates - Insider Monkey
Recursion Pharmaceuticals Stock Surges: What’s Happening? - timothysykes.com
RXRX Stock’s Impressive Surge: A Closer Look - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 10.7% After Positive REC-4881 Trial Data And Rising Analyst Focus - simplywall.st
Recursion Pharmaceuticals Inc Stock Analysis and ForecastLow Risk Investment Ideas & AI-Based Insights for Consistent Profits - earlytimes.in
Recursion Pharmaceuticals, Inc. (RXRX) Investor Outlook: Uncovering a 60% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - AOL.com
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Mispriced After Volatile Share Performance And Ongoing Tech Partnerships - simplywall.st
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline - MSN
Should J.P. Morgan’s REC-4881 Upgrade and TUPELO Data Require Action From Recursion (RXRX) Investors? - Yahoo Finance
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):